Target intelligence / Profile preview

Immunoglobulin lambda variable 3-26 (pseudogene) (IGLV3-26)

Target
IGLV3-26
Molecular classification
Immunoglobulin variable region gene, Pseudogene, Other
01

Overview

Immunoglobulin lambda variable 3-26 (IGLV3-26) is a pseudogene within the immunoglobulin lambda variable region gene family. In general, immunoglobulin variable genes encode the variable domains of light chains in antibodies, contributing to the antigen-binding diversity of the immune response. However, IGLV3-26 specifically is classified as a pseudogene, meaning that it does not produce a functional protein and is not involved in encoding functional antibody chains. It is located within the immunoglobulin lambda locus and is part of the broader immunoglobulin (antibody) gene complex, which undergoes somatic rearrangement to produce the antigen-binding diversity essential for adaptive immunity. Because IGLV3-26 is a pseudogene and not known to be expressed as a functional protein, it is not considered a drug target, receptor, enzyme, or direct participant in disease processes[1][2][5][7]. Key points: - The official gene symbol is IGLV3-26. - It is a pseudogene, so it is not expressed as a functional protein[5]. - While functional immunoglobulin lambda variable genes play a role in immune defense, a pseudogene like IGLV3-26 does not encode a protein and therefore is not considered a therapeutic target or biomarker. - There are no known drugs, mechanisms of action, or clinical safety concerns associated with this pseudogene. - Alternative names found include IGLV326 and V2-18P[2][5].

Other names
IGLV326V2-18P
02

Biological functions

Not functionally expressed (pseudogene)Other
03

Disease associations

Other

Beyond the preview

Go deeper on Immunoglobulin lambda variable 3-26 (pseudogene) (IGLV3-26).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin lambda variable 3-26 (pseudogene) (IGLV3-26).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call